Sumitomo Dainippon Pharma Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Sumitomo Dainippon Pharma Oncology's estimated annual revenue is currently $43.6M per year.
- Sumitomo Dainippon Pharma Oncology's estimated revenue per employee is $201,000
Employee Data
- Sumitomo Dainippon Pharma Oncology has 217 Employees.
- Sumitomo Dainippon Pharma Oncology grew their employee count by 19% last year.
Sumitomo Dainippon Pharma Oncology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP Head US Research | Reveal Email/Phone |
2 | Associate director, Translational research | Reveal Email/Phone |
3 | Chief Medical Officer Global Head Development | Reveal Email/Phone |
4 | Associate Project Manager | Reveal Email/Phone |
5 | Manager, R&D IT | Reveal Email/Phone |
6 | Scientist | Reveal Email/Phone |
Sumitomo Dainippon Pharma Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Sumitomo Dainippon Pharma Oncology?
Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology. SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Our robust and diverse pipeline of preclinical and advanced-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology. SDP Oncology encompasses discovery research, external innovation, clinical development and commercialization. The company has teams in Lehi, Utah, Tokyo and Osaka, Japan as well as Cambridge, Massachusetts. At SDP Oncology, we believe in the power of science ￃﾢ￢ﾂﾬ￢ﾀﾜ and our people ￃﾢ￢ﾂﾬ￢ﾀﾜ to usher in breakthrough innovation that will positively impact patients with cancer today and for generations to come.
keywords:N/A
N/A
Total Funding
217
Number of Employees
$43.6M
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sumitomo Dainippon Pharma Oncology News
DSP-0390, an investigational new agent developed by Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, is an inhibitor of...
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of DSP-5336 in Patients with Acute Leukemia with and without...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.2M | 217 | -1% | $395.5M |
#2 | $43M | 217 | N/A | N/A |
#3 | $43M | 217 | 11% | N/A |
#4 | $15M | 218 | 0% | $30M |
#5 | $36M | 218 | 23% | N/A |